amp biosimilars AG Strengthens Management And Supervisory Boards

- Gunnar Janssen switching from the Supervisory as CFO to the Management Board

- Dr Thomas Zimmer (formerly with Boehringer Ingelheim) appointed new Chairman of the Supervisory Board

- Strengthening the management ahead of significant new contracts

Hamburg, Germany, May 20, 2015 - amp biosimilars AG (ISIN: DE000A0SMU87), a company specializing in the development of high quality biosimilars, is strengthening its Management and Supervisory Boards.

Gunnar Janssen has stepped down as Deputy Chairman of the Supervisory Board with immediate effect and will continue as Chief Financial Officer, responsible for Finance, Controlling, and Investor Relations. The expansion of the Management Board comes in the run-up of pending contracts with international partners. Mr Janssen, who began his career with Deutsche Bank and has over 25 years of experience in the financial sector in Frankfurt, Zurich, and London, will be an asset to amp biosimilars AG. Mr Janssen has served in various leadership positions, including for Deutsche Bank Capital Markets, Credit Suisse First Boston, Barclays, Commerzbank Securities, Lehman Brothers, and Donaldson, Lufkin & Jenrette. Throughout his career, Mr Janssen has been responsible for numerous capital market transactions and has built up a comprehensive network in corporate finance and capital markets. Most recently, he served as Chairman of the Board and Managing Director of German Private Equity GmbH.

Dr Thomas Zimmer will assume Mr Janssen's role on the Supervisory Board and direct the body as its new Chairman. Dr Zimmer has over 34 years of experience in the pharmaceutical industry, including in various senior leadership positions at Boehringer Ingelheim, where he also gained experience abroad in locations such as Brazil, Spain, and the USA. He implemented the European manufacturing alliance, where he was responsible for product transfers and for transition management of local manufacturing plants moving from national to international product supply. This was followed by responsibilities as plant manager at several locations in France and as Senior Vice President of Global Quality Management for 30 plants in the fields of human drugs, biopharmaceuticals, and animal health. Dr Zimmer is rated a Qualified Person under the German Medicines Act (AMG) and was chief GMP auditor for Boehringer Ingelheim. He has established an extensive network in the pharmaceutical industry and, as Vice President of European Operations, is manager for the International Society for Pharmaceutical Engineering (ISPE), the largest association in the manufacturing pharmaceutical industry, with 20,000 members in more than 90 countries. amp biosimilars AG will benefit from the new Chairman of the Supervisory Board. Dr Zimmer will bring in his experience and his network, focusing in particular on international production, quality assurance, and supply chain.

"For us, strengthening the Management and Supervisory Boards is an essential step towards the successful implementation of our growth strategy. Given the massive volume of our pending partnerships, the past few weeks have shown just how important it is for us going forward that we have highly experienced leaders occupying key positions," explains Dr Marc W. Hentz, Chief Executive Officer of amp biosimilars AG. "Both Mr Janssen and Dr Zimmer offer the experience and network we need to enhance our strengths in key areas. The company's three principal bodies, the Management Board, the Supervisory Board, and the Scientific Board, are now fully staffed and ready to shape corporate growth in the coming years, with lasting effect. In my view, the next few weeks will show just how capable our high-caliber team is, and demonstrate how well-positioned our company is in the rapidly growing biosimilars market".

About amp biosimilars AG:

amp biosimilars AG develops high quality biosimilars to meet growing demand on global therapeutic markets and is one of the most innovative and dynamic biosimilar companies in Europe. The company is headquartered in Hamburg and run by a team of leading industry experts. The development of a wide variety of biosimilars will provide patients around the world with access to life-improving and life-saving therapies. The combination of a research platform with state-of-the-art analytics, process technology and clinical expertise as well as regulatory know-how, makes amp biosimilars AG one of the leading companies for biosimilar development and marketing. Thanks to an international network of leading pharmaceutical companies, amp biosimilars AG also has direct access to the strongest growing markets in the world. With this approach amp biosimilars AG has a key position in one of the fastest growing life science markets in the near future. amp biosimilars AG has been listed on the Munich Stock Exchange since April 1, 2015. For more information please go to www.ampbiosimilars.com

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.